The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 10, 2012, Pages 972-979

  Marcus, E A ^a,b   Inatomi, N ^c   Nagami, G T ^b   Sachs, G ^a   Scott, D R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; UREA;

ACIDITY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL MEMBRANE; BACTERIAL SURVIVAL; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BIOSYNTHESIS; CELL DIVISION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; HELICOBACTER PYLORI; NONHUMAN; PENICILLIN BINDING PROTEIN GENE; PH; PRIORITY JOURNAL; STOMACH JUICE;

AMPICILLIN; ANTI-BACTERIAL AGENTS; GASTRIC JUICE; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; POLYMERASE CHAIN REACTION; UREA;

EID: 84867582618     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12059     Document Type: Article

References (41)

1. Suerbaum S, Michetti P,. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-86.
2. Blaser MJ,. Helicobacter pylori: its role in disease. Clin Infect Dis 1992; 15: 386-91.
3. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ,. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991; 325: 1132-6.
4. Parsonnet J,. Gastric adenocarcinoma and Helicobacter pylori infection. West J Med 1994; 161: 60. (Pubitemid 24230983)
5. Parsonnet J, Friedman GD, Vandersteen DP, et al,. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-31.
6. International Agency for Research on Cancer. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 177-240.
7. Blaser MJ,. Helicobacter pylori and esophageal disease: wake-up call? Gastroenterology 2010; 139: 1819-22.
8. Sachs G, Scott DR,. Helicobacter pylori: eradication or preservation. F1000 Med Rep 2012; 4: 7.
9. Malfertheiner P, Megraud F, O'Morain CA, et al,. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
10. Gisbert JP, Gonzalez L, Calvet X,. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter 2005; 10: 157-71. (Pubitemid 40769946)
11. Lind T, Megraud F, Unge P, et al,. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 248-53. (Pubitemid 29055345)
12. Saleem A, Qasim A, O'Connor HJ, O'Morain CA,. Pylera for the eradication of Helicobacter pylori infection. Expert Rev Anti Infect Ther 2009; 7: 793-9.
13. Nakao M, Malfertheiner P,. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter 1998; 3: 21-7. (Pubitemid 128656406)
14. +)-ATPase by omeprazole. Biochim Biophys Acta 1985; 817: 25-32. (Pubitemid 15011675)
15. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC,. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997; 39: 5-12. (Pubitemid 27092263)
16. Scott D, Weeks D, Melchers K, Sachs G,. The life and death of Helicobacter pylori. Gut 1998; 43 (Suppl. 1): S56-60. (Pubitemid 28338114)
17. Sjostrom JE, Larsson H,. Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant. J Med Microbiol 1996; 44: 425-33. (Pubitemid 26180054)
18. Scott DR, Marcus EA, Wen Y, Oh J, Sachs G,. Gene expression in vivo shows that Helicobacter pylori colonizes an acidic niche on the gastric surface. Proc Natl Acad Sci U S A 2007; 104: 7235-40. (Pubitemid 47186038)
19. Jain R, Danziger LH,. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des 2004; 10: 3045-53. (Pubitemid 39242900)
20. Marcus EA, Moshfegh AP, Sachs G, Scott DR,. The periplasmic alpha-carbonic anhydrase activity of Helicobacter pylori is essential for acid acclimation. J Bacteriol 2005; 187: 729-38. (Pubitemid 40096259)
21. Rozen S, Skaletsky H,. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000; 132: 365-86.
22. Wen Y, Marcus EA, Matrubutham U, Gleeson MA, Scott DR, Sachs G,. Acid-adaptive genes of Helicobacter pylori. Infect Immun 2003; 71: 5921-39. (Pubitemid 37205645)
23. McColl KE,. The elegance of the gastric mucosal barrier: designed by nature for nature. Gut 2012; 61: 787-8.
24. Baumgartner HK, Montrose MH,. Regulated alkali secretion acts in tandem with unstirred layers to regulate mouse gastric surface pH. Gastroenterology 2004; 126: 774-83. (Pubitemid 38298326)
25. Henriksnas J, Phillipson M, Storm M, Engstrand L, Soleimani M, Holm L,. Impaired mucus-bicarbonate barrier in Helicobacter pylori-infected mice. Am J Physiol Gastrointest Liver Physiol 2006; 291: G396-403. (Pubitemid 44330159)
26. Hunt RH,. Hp and pH-the relevance of gastric acid to the treatment of Helicobacter pylori infection. J Gastroenterol 1994; 29 (Suppl. 7): 128-33. (Pubitemid 24238505)
27. Labenz J, Stolte M, Blum AL, et al,. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995; 37: 39-43.
28. Sugimoto M, Furuta T, Shirai N, et al,. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007; 12: 317-23. (Pubitemid 47196333)
29. Kim JI, Park SH, Kim JK, Chung IS, Chung KW, Sun HS,. The effects of nocturnal acid breakthrough on Helicobacter pylori eradication. Helicobacter 2002; 7: 331-6. (Pubitemid 36068491)
30. Atherton JC, Cockayne A, Balsitis M, Kirk GE, Hawkey CJ, Spiller RC,. Detection of the intragastric sites at which Helicobacter pylori evades treatment with amoxycillin and cimetidine. Gut 1995; 36: 670-4.
31. Yang JC, Wang HL, Chern HD, et al,. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. Pharmacotherapy 2011; 31: 227-38.
32. Furuta T, Sugimoto M, Shirai N, Ishizaki T,. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics 2007; 8: 1199-210. (Pubitemid 47578229)
33. Sugimoto M, Shirai N, Nishino M, et al,. Rabeprazole 10 mg q.d.s. deceases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther 2012; 36: 627-34.
34. Attumi TA, Graham DY,. Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study. J Gastroenterol Hepatol 2012; 27: 59-61.
35. Graham DY, Javed SU, Keihanian S, Abudayyeh S, Opekun AR,. Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. J Gastroenterol 2010; 45: 816-20.
36. Dent J, Kahrilas PJ, Hatlebakk J, et al,. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008; 103: 20-6.
37. Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Inatomi N,. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 2011; 337: 797-804.
38. Hunt RH, Armstrong D, Yaghoobi M, James C,. The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. Aliment Pharmacol Ther 2010; 31: 648-57.
39. Hunt RH, Armstrong D, Yaghoobi M, et al,. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008; 28: 187-99. (Pubitemid 351861964)
40. Shin JM, Inatomi N, Munson K, et al,. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl] -N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther 2011; 339: 412-20.
41. Tomb JF, White O, Kerlavage AR, et al,. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997; 388: 539-47. (Pubitemid 27339996)